CV Therapeutics Discloses Ranexa Sales (AP via Yahoo! Finance)
Biopharmaceutical company CV Therapeutics Inc. expects fourth-quarter net revenue of about $21 million from sales of its chronic angina drug, Ranexa, according to a Securities and Exchange Commission filing Tuesday.